## Enteric Fever Outbreaks in Africa: Same old Foe but Emerging New Challenges in Management

## Sam Kariuki





## Lecture outline

- Epidemiology of typhoid in Africa
- New clonal expansions and Antimicrobial Resistance
- Current issues on diagnosis
- Prospects for vaccine use in disease prevention strategies

# Introduction

- Few population-based data on incidence and mortality due to salmonellosis in Africa (SETA initiative)
- Most data from hospital-based studies of communityacquired bloodstream infection
  - Non-Typhi Salmonella predominate in west, central, east, and southern Africa
  - More cases of S. Typhi now reported from informal settlements in sub-Saharan Africa
  - Differences in regional prevalence and epidemiology is poorly understood

## A long way to go on matters overcrowding and sanitation


Mukuru kwa Njenga and Mukuru Reuben are among the many villages in the larger slum

#### **Catchment population for Mukuru**


Description	Population	
Total catchment population	150,000	
Children under 1yr(12months)	22,000	
Children under 5 yrs (60months)	30,000	
Children under 15 yrs	37,000	
Adults (24-59yrs)	50,000	
Elderly (over 60yrs)	11,000	



## **Endemic and Hyperedemic typhoid regions**




## **Global Collection and analysis of S. Typhi**



Wong VK, et al. Nat Genet. 2015 Jun;47(6):632-9.

#### In sub-Saharan Afria, where does Typhoid Fever cluster?



#### West Africa:

**Molecular Surveillance Identifies Multiple Transmissions of Typhoid in West Africa**. *International Typhoid Consortium., Wong VK, et al. PLoS Negl Trop Dis. 2016 Sep 22;10(9):* 

#### **South Africa:**

**Typhoid Fever in South Africa in an Endemic HIV Setting.** *Keddy KH,et al; GERMS-SA..PLoS One. 2016 Oct 25;11(10):.* 

Carriage prevalence of Salmonella enterica serotype Typhi in gallbladders of adult autopsy cases from Mozambique.

Lovane L, etal. J Infect Dev Ctries. 2016 Apr 28;10(4):410-2.

## A Qualitative Study Investigating Experiences, Perceptions, and Healthcare System Performance in Relation to the Surveillance of Typhoid Fever in Madagascar.

Pach A, et al. Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S69-75.

**Rapid emergence of multidrug resistant, H58-lineage Salmonella Typhi in Blantyre, Malawi.** *Feasey NA, et al PLoS Negl Trop Dis. 2015 Apr 24;9(4):.* 

#### **Central Africa:**

Salmonella Typhi in the Democratic Republic of the Congo: fluoroquinolone decreased susceptibility on the rise.

Lunguya O, et al PLoS Negl Trop Dis. 2012;6(11):e1921

#### **East Africa:**

Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia.

Kariuki S, et al. J Clin Microbiol. 2010 Jun;48(6):2171-6.

**Diagnosis of imported Ugandan typhoid fever based on local outbreak information: A case report.** *Ota S, et al. J Infect Chemother.* 2016 Nov;22(11):770-773.

A large and persistent outbreak of Typhoid fever caused by consuming contaminated water and street-vended beverages: Kampala, Uganda, January - June 2015.

Kabwama SN, et al. BMC Public Health. 2017 Jan 5;17(1):23.

<u>A large outbreak of typhoid fever associated with a high rate of intestinal perforation</u> in Kasese District, Uganda, 2008-2009.

*Neil KP, et al. Clin Infect Dis. 2012 Apr;54(8):1091-9.* 

Massive lineage replacements and cryptic outbreaks of Salmonella Typhi in eastern and southern Africa.

Wirth T. Nat Genet. 2015 Jun;47(6):565-7.

Diagnosis and Treatment of Typhoid Fever and Associated Prevailing Drug Resistance in Northern Ethiopia.


Wasihun AG, et al Int J Infect Dis. 2015 Jun;35:96-102.

#### **Transcontinental MDR spread:**


A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa.

Al-Emran HM, et al Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S42-6.

#### In all endemic settings MDR is a major challenge in Africa



#### Kenya as an early hub of S. Typhi H58 from SE Asia




What are the major challenges in tackling Typhoid in SSA?

# **Challenges in Diagnosis**

## Clinical Diagnosis

- •High index of suspicion
- Knowledge of the local epidemiology
- Clinical presentation is usually non specific



# Laboratory tests: from when are they useful?

- Blood culture or BM culture : Week 1
- Serological Methods : Week 2 (Widal Test most common)
- Stool Ag Test : Week 2
- Urine culture : Week 4
- PCR : Week 1
- WGS and metabolomics technology can be adopted for bedside Dx

Andrew & Ryan, Vaccine. 2015 Jun 19;33 Suppl 3:C8-15.

#### Diagnostic accuracy of the TUBEX-TF and OnSite Typhoid IgG/IgM Combo tests with culture as the gold standard (Zimbabwe outbreak of 2014)

Test	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
TUBEX-TF (n = 131)	100	94.12	63.16	100
OnSite Typhoid IgG/IgM Combo (n = 136)	100	94.34	63.16	100

Only point-of-care rapid tests available, but LOW to MODERATE sensitivity and specificity

Talupiwa et al., BMC Res Notes. 2015 Feb 24;8:5

Challenges in treatment options and vaccine use in Africa

# Issues of antibiotic Rx in face of MDR S. Typhi

- For MDR infections fluoroquinolones widely used for treatment.
- For fully susceptible S. Typhi (ciprofloxacin MIC< 0.06 μg/mL) Rx very effective
- Later generation fluoroquinolone, gatifloxacin, clinically more effective against MDR infections
- Azithromycin MIC  $\leq 16 \,\mu g/mL$
- Ceftriaxone and cefotaxime, reliable reserve drugs particularly for hospital admitted cases

## Vaccines

- WHO recommends targeted vaccination of high risk populations as a short- to medium-term measure.
- Locally, only private clinics stock Vi conjugate vaccine for travel vaccination and for workers in hospitality industry
- Prices still too high for widespread public health use
- Governments in Africa have not prioritized use of vaccine even in endemic settings

# **Conclusion 1**

- With increasing informal settlements with little or no infrastructure, we will continue to experience outbreaks, we have to prepare!
- Accurate diagnosis a major challenge in our settings – we need to adopt simple affordable rapid kits that can be deployed under field conditions.
- Burden of disease data and economic implications important to document as these mobilize action!

# **Conclusion 2**

- Resistance to commonly available antibiotics and high cost of effective alternatives should persuade policy makers to consider low cost vaccine, with options for technology transfer and bulk purchase
- Improving hygiene, clean water supply and reduced overcrowding long term goals

## Acknowledgement

- KEMRI, Nairobi  $\succ$
- ➢ Cecilia Mbae
- ➢ Frida Njeru
- Ronald Ngetich
- Susan Kavai
- > Anthony
- ➢ Field workers

Aga Khan Hospital, Nairobi Gunturu Revathi

- Funding
- Wellcome Trust
- NIH Grant 5R01AI099525

### Study site clinicians

Sanger Institute/University of Cambridge Gordon Dougan Vanessa Wong Kate Auger Sally Kay

#### Field workers

